DiaMedica Therapeutics, Inc.

Redefine What’s Possible: a Potential New Treatment Paradigm for Stroke Patients

DiaMedica Therapeutics is committed to improving the lives of individuals battling serious vascular diseases by developing innovative therapies. With an initial focus on acute ischemic stroke (AIS), we are dedicated to advancing patient care through a novel approach that centers around improving collateral circulation, with the benefit of a 24-hour window following a stroke in which to initiate treatment. The stark reality is that less than 20% of stroke patients are eligible for an approved treatment in the United States today. DiaMedica’s mission is to revolutionize the treatment landscape for the 80% of patients who have been left with no therapeutic alternative.

More About DiaMedica

Advancing Patient Care with Innovative Treatments

Our lead candidate, DM199, is a potential treatment for several health conditions in which the patient is experiencing low levels of the KLK1 protein.

Acute Ischemic Stroke (AIS)

There is a significant unmet need for a treatment option for AIS patients. AIS is the leading cause of combined mortality and morbidity worldwide, and 87% of all strokes are ischemic. We are initially studying DM199 as a treatment option for patients arriving at the hospital within 24 hours of stroke onset and who do not have a therapeutic treatment option. These patients include those who are not eligible to receive tPA, due to either the small 4.5-hour treatment window or who are at risk of severe bleeding, and those who are not eligible for mechanical thrombectomy which is limited to blockages occurring in the large arteries bringing blood to the brain (i.e. the carotid).

DM199 for Acute Ischemic Stroke (AIS)

Cardio-Renal Disease

According to the National Kidney Foundation, 30 million Americans struggle with chronic kidney disease, 1 in 3 adults are at risk for CKD and it is the 9th leading cause of death in the United States.  CKD can adversely impact ones quality of life and potentially lead to end-stage renal disease requiring dialysis or kidney transplant. We are diligently working on a treatment to reduce blood pressure and improve kidney function in order to avoid further damage and disease progression.

Intended to Replenish KLK1 Levels

DiaMedica’s investigational drug product candidate, DM199, is intended to restore normal levels of the KLK1 protein in patients. The restoration of this protein is intended to allow patients to naturally regulate their blood flow and maintain vascular homeostasis as well as reduce inflammation and oxidative stress.

View Our Pipeline

Latest News

View all news

Stock Information

View Investor Relations